Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InSite Vision signs license deal with Inspire
The agreement covers commercialization rights in the US and Canada for the drug which is currently under new drug application review by the FDA. According to InSite, the
The agreement covers commercialization rights in the US and Canada for the drug which is currently under new drug application review by the FDA. According to InSite, the
A conditional marketing authorization was granted to Prezista because of its benefits for HIV-1 infected patients, however, more evidence is yet to be provided. Additional safety and efficacy
The subsequent offering period will now expire on February 15 2007 and will not be further extended, GlaxoSmithKline said. Praecis stockholders have now tendered a total of approximately
These lower dosage strengths are in addition to the 75mg capsule already registered and have been developed mainly for use in children for seasonal and pandemic influenza, as
This clinical submission is based on data from a phase III registrational trial. The trial results for progression-free survival (PFS) were highly statistically significant. Satraplatin was granted fast
Valeant markets nabilone in the US and Canada under the brand name Cesamet. Nabilone is indicated for use in the treatment of nausea and vomiting associated with cancer
It is believed that the raid was conducted by the Food and Drug Administration but the agency has not disclosed the reasons behind the search. Paper and electronic
The study was designed to evaluate combretastatin A4 phosphate (CA4P). Combretastatin represents a new class of therapeutic compounds known as vascular targeting agents. The primary efficacy endpoint of
One application is filed in support of a proposed new indication for the use of Januvia, as an adjunct to diet and exercise, in combination with metformin as
The phase IIb trial will be conducted at 30 sites in the US, where 1,000 potential subjects are being recruited. “Given the remarkable safety profile of NB-001 and